Abstract | AIM: METHODS AND RESULTS: Four hundred patients with hypercholesterolemia ( LDL-C >or=140 mg/dL) and a maximum IMT of >or=1.1 mm will be treated for 24 months either with intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, and 70 mg/dL for secondary prevention) or conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007). The primary endpoint will be the percent change of mean-IMT and the objectives of the study are to compare the two protocols. CONCLUSION: The JART trial is a prospective, randomized, open-label, blinded end-point evaluation, multi-center, parallel-group, comparative study to examine the regressive effect of intensive lipid-lowering therapy with statins on atherosclerosis by evaluating IMT in the Japanese population.
|
Authors | Masahiko Kurabayashi, Ichiro Sakuma, Ryuzo Kawamori, Hiroyuki Daida, Tsutomu Yamazaki, Masayuki Yoshida, Mitsumasa Hata, Izuru Masuda, Kohei Kaku, Hiroyoshi Yokoi, Junji Kishimoto, Ryuji Nohara |
Journal | Journal of atherosclerosis and thrombosis
(J Atheroscler Thromb)
Vol. 17
Issue 4
Pg. 416-22
(Apr 30 2010)
ISSN: 1880-3873 [Electronic] Japan |
PMID | 20215710
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticholesteremic Agents
- Cholesterol, LDL
- Fluorobenzenes
- Pyrimidines
- Sulfonamides
- Rosuvastatin Calcium
- Pravastatin
|
Topics |
- Adult
- Anticholesteremic Agents
(therapeutic use)
- Cholesterol, LDL
(blood)
- Coronary Artery Disease
(drug therapy, pathology)
- Female
- Fluorobenzenes
(therapeutic use)
- Humans
- Japan
- Male
- Pravastatin
(therapeutic use)
- Prospective Studies
- Pyrimidines
(therapeutic use)
- Rosuvastatin Calcium
- Sulfonamides
(therapeutic use)
- Treatment Outcome
- Tunica Intima
(drug effects)
- Tunica Media
(drug effects)
- Young Adult
|